Who owns Trevi Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TRVI from SEC Form 13F filings across 224 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 224 institutions disclosed 151.2M shares of Trevi Therapeutics, Inc. worth $2.17B — about 94.7% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
224
13F holders
$2.17B
value, 2026 filers
94.7%
of shares outstanding (151.2M sh)
38
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of TRVI's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 13.6M | $195.2M | 0.0% | 8.5% | +8.5% |
| 2 | NEA Management Company, LLC | 13.2M | $189.3M | 13.9% | 8.3% | 0.0% |
| 3 | BlackRock, Inc. | 12.3M | $176.0M | 0.0% | 7.7% | +10.2% |
| 4 | Frazier Life Sciences Management, L.P. | 9.5M | $136.6M | 3.4% | 6% | -4.0% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 6.2M | $89.3M | 0.0% | 3.9% | +9.7% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $87.5M | 0.0% | 3.8% | +10.5% |
| 7 | Vivo Capital, LLC | 4.2M | $60.6M | 6.7% | 2.6% | -17.0% |
| 8 | Assenagon Asset Management S.A. | 3.5M | $50.5M | 0.0% | 2.2% | +131.2% |
| 9 | STATE STREET CORP | 3.3M | $46.9M | 0.0% | 2% | +8.1% |
| 10 | MARSHALL WACE, LLP | 3.2M | $45.1M | 0.0% | 2% | +17.8% |
| 11 | MPM BIOIMPACT LLC | 3.0M | $42.7M | 3.2% | 1.9% | -3.1% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3.0M | $42.4M | 0.0% | 1.9% | +1.1% |
| 13 | Soleus Capital Management, L.P. | 2.7M | $39.1M | 1.4% | 1.7% | +131.2% |
| 14 | EVENTIDE ASSET MANAGEMENT, LLC | 2.6M | $36.5M | 0.5% | 1.6% | -4.1% |
| 15 | FRONTIER CAPITAL MANAGEMENT CO LLC | 2.4M | $34.2M | 0.4% | 1.5% | -22.1% |
| 16 | First Light Asset Management, LLC | 2.4M | $34.2M | 2.0% | 1.5% | +13.8% |
| 17 | Artia Global Partners LP | 2.2M | $31.7M | 6.4% | 1.4% | 0.0% |
| 18 | ALLIANCEBERNSTEIN L.P. | 2.2M | $31.6M | 0.0% | 1.4% | -6.3% |
| 19 | ACORN CAPITAL ADVISORS, LLC | 2.1M | $30.7M | 8.4% | 1.3% | 0.0% |
| 20 | Pictet Asset Management Holding SA | 2.0M | $27.9M | 0.0% | 1.2% | -3.1% |
| 21 | Affinity Asset Advisors, LLC | 1.8M | $25.8M | 1.0% | 1.1% | 0.0% |
| 22 | EMERALD ADVISERS, LLC | 1.8M | $25.7M | 0.7% | 1.1% | -0.1% |
| 23 | Pivotal bioVenture Partners Investment Advisor LLC | 1.7M | $25.0M | 9.9% | 1.1% | 0.0% |
| 24 | Saturn V Capital Management LP | 1.6M | $22.5M | 3.3% | 1% | +49.6% |
| 25 | Siren, L.L.C. | 1.5M | $21.8M | 0.5% | 1% | -14.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.